ICU Medical (NASDAQ:ICUI) Research Coverage Started at Needham & Company LLC

Needham & Company LLC assumed coverage on shares of ICU Medical (NASDAQ:ICUI) in a report released on Friday, Briefing.com reports. The brokerage set a “hold” rating on the medical instruments supplier’s stock.

A number of other research analysts also recently commented on the stock. Raymond James raised shares of ICU Medical from a “market perform” rating to an “outperform” rating and set a $135.00 price objective on the stock in a research report on Monday. KeyCorp lifted their target price on shares of ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $127.00.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $120.55 on Friday. ICU Medical has a 12 month low of $78.28 and a 12 month high of $185.63. The company has a quick ratio of 1.09, a current ratio of 2.61 and a debt-to-equity ratio of 0.76. The stock has a market cap of $2.94 billion, a PE ratio of -49.20 and a beta of 0.73. The business has a fifty day simple moving average of $104.49 and a 200-day simple moving average of $100.81.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.06. ICU Medical had a positive return on equity of 5.38% and a negative net margin of 2.63%. The firm had revenue of $566.66 million during the quarter, compared to analyst estimates of $553.15 million. On average, sell-side analysts anticipate that ICU Medical will post 3.5 EPS for the current fiscal year.

Insider Activity at ICU Medical

In related news, insider Ben Sousa sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $105.55, for a total transaction of $211,100.00. Following the transaction, the insider now owns 1,319 shares of the company’s stock, valued at $139,220.45. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Elisha W. Finney sold 300 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $104.95, for a total transaction of $31,485.00. Following the completion of the sale, the director now owns 2,129 shares in the company, valued at approximately $223,438.55. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Ben Sousa sold 2,000 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $105.55, for a total value of $211,100.00. Following the transaction, the insider now directly owns 1,319 shares in the company, valued at approximately $139,220.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,839 shares of company stock valued at $1,546,014. 6.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ICU Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of ICU Medical by 0.5% in the first quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after purchasing an additional 11,991 shares during the period. FMR LLC raised its holdings in ICU Medical by 89.9% in the 3rd quarter. FMR LLC now owns 1,124,995 shares of the medical instruments supplier’s stock worth $133,886,000 after acquiring an additional 532,483 shares during the period. Schroder Investment Management Group raised its holdings in ICU Medical by 35.8% in the 4th quarter. Schroder Investment Management Group now owns 433,852 shares of the medical instruments supplier’s stock worth $43,272,000 after acquiring an additional 114,344 shares during the period. Ameriprise Financial Inc. lifted its position in ICU Medical by 28.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 324,867 shares of the medical instruments supplier’s stock worth $38,662,000 after acquiring an additional 71,258 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC boosted its holdings in ICU Medical by 109.4% during the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after acquiring an additional 145,485 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.